Choi v. Restaino

CourtCalifornia Court of Appeal
DecidedJune 21, 2016
DocketB257480A
StatusPublished

This text of Choi v. Restaino (Choi v. Restaino) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Choi v. Restaino, (Cal. Ct. App. 2016).

Opinion

6/21/16 Opinion following order vacating prior opinion CERTIFIED FOR PARTIAL PUBLICATION*

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA

SECOND APPELLATE DISTRICT

DIVISION THREE

WANKYU CHOI et al., B257480

Plaintiffs and Respondents; (Los Angeles County Super. Ct. No. BC501173) MARY RESTAINO et al.,

Plaintiffs and Appellants,

v.

MARIO BADESCU SKIN CARE, INC., et al.,

Defendants and Respondents.

APPEAL from a judgment of the Superior Court of Los Angeles County, William F. Highberger, Judge. Affirmed. The C2 Law Group, Erica E. Hayward; The Rudd Law Firm, Christopher L. Rudd; Whitfield Bryson & Mason, Gary E. Mason and Esfand Y. Nafisi for Plaintiffs and Appellants Mary Restaino, Geoffrey Yu, Theresa Stern Valentic, Betty Huang and Zoe Herold. Law Offices of Ronald A. Marron, Ronald A. Marron, Skye Resendes; and C. Benjamin Nutley for Plaintiff and Appellant Donna McLaren.

* Pursuant to California Rules of Court, rules 8.1100 and 8.1110, this opinion is certified for partial publication. The portions of this opinion to be deleted from publication are those portions enclosed within double brackets, [[ ]]. Law Office of Young W. Ryu, Young W. Ryu; Law Offices of Gerald S. Ohn and Gerald S. Ohn for Plaintiffs and Respondents. Tucker Ellis, Ronie M. Schmelz and Rebecca A. Lefler for Defendants and Respondents. _________________________ INTRODUCTION Jae K. Lee and Wankyu Choi sued Mario Badescu Skin Care, Inc. and Mario Badescu for marketing and labeling two face creams without disclosing all of the ingredients. Plaintiffs sought economic damages and equitable relief on behalf of themselves and a nationwide class of face cream purchasers. Before the class was certified, defendants agreed to settle the action. Nine class members, who timely objected, appeal raising numerous contentions. In the unpublished portion of this opinion, we hold that the objectors have not demonstrated error. In the published portion of this opinion, we hold that the one-time publication of the notice of settlement did not violate the Consumers Legal Remedies Act (Civ. Code, § 1750 et seq. (CLRA)). Accordingly, we affirm the judgment. FACTUAL AND PROCEDURAL BACKGROUND 1. The complaint In December 2012, the Korean Ministry of Food and Drug Safety suspended the sales of defendants’ Healing Cream after testing revealed the product contained two unlabeled corticosteroids, hydrocortisone and triamcinolone acetonide. The recall advised consumers to cease using the cream and warned that long-term use of steroids could lead to skin atrophy and enlarged capillaries. Plaintiffs Lee and Choi (together plaintiffs, the named plaintiffs, or class representatives) purchased defendants’ Healing Cream and used it.1 Their attorneys had

1 The two named plaintiffs attached declarations to their response to objections, in which they stated they “personally used Mario Badescu Healing Cream” after receiving it.

2 the purchased creams tested by an independent laboratory and discovered the presence of 2610 µg/g of hydrocortisone and 1899 µg/g of triamcinolone acetonide. The named plaintiffs filed this consumer class action against defendants on behalf of all persons residing in the United States who purchased defendants’ Healing Cream. The operative complaint alleged that defendants represented through marketing, advertising, labeling, and other forms of promotion, that the Healing Cream prevented acne scars and speeded up the healing process for irritated or acne-erupted skin,2 but “failed to disclose that [defendants’] Healing Cream products contain levels of Hydrocortisone and Triamcinolone Acetonide, which are steroid substances with serious side effects. [¶] . . . [¶] Triamcinolone is a synthetic corticosteroid used to treat various skin conditions. . . . Triamcinolone Acetonide . . . is a DOCTOR’S PRESCRIPTION ONLY medicated cream . . . .” The complaint alleged that the class overpaid for the product because its value was diminished at the time it was sold to consumers. Had the class members been aware that the cream contained hydrocortisone and triamcinolone acetonide, they would not have purchased the product, would have paid less for it, or would have purchased another competing product. The complaint asserted causes of action for violation of the CLRA; fraudulent concealment; false advertising in violation of Business and Professions Code section 17500, all of which violated Business and Professions Code section 17200; breach of express and implied warranties; and false and misleading advertisement in violation of the Magnuson-Moss Warranty Act (15 U.S.C. § 2301 et seq.). Plaintiffs sought an order certifying a nationwide class and a California subclass, and sought injunctive relief, restitution, monetary damages, punitive damages, and attorney fees. Defendants stopped selling the creams after the complaint was filed.

2 Plaintiffs alleged that the Healing Cream’s label listed the ingredients as “ ‘Balsam (Myroxylon Pereirae Resin) Peru, Polyglycerlmenthacrylate (and) Propylene Glycol, Herbal Extract, Bismuth Subgallate,’ ” but that “[d]efendants did not disclose that the Healing Cream contained STEROIDS.”

3 [[Begin nonpublished portion.]] 2. The litigation In April 2013, the parties filed a joint initial status conference and class action response statement. Defendants anticipated moving for summary judgment to address preemption, standing, causation, and damages. Commencing in May 2013, after demurrers, motions to strike, and amendments to the complaint, plaintiffs served defendants with approximately 300 discovery requests in the form of multiple sets of interrogatories, demands for production, and requests for admission. Defendants submitted multiple responses and supplemented responses. Also in May 2013 when plaintiffs served their first round of discovery, their attorneys began preparing for a settlement meeting and interviewed a class action administrator about settlement issues. Pursuant to trial court order, in August 2013, the parties negotiated a protective order under which defendants produced 359 pages of documents concerning the revenue from the sale of their cream. Based on defendants’ discovery responses, plaintiffs added to their motion for final approval claims that in addition to the Healing Cream, defendants failed to disclose that their Control Cream also contained levels of hydrocortisone and triamcinolone acetonide. Defendants reported that they sold approximately 160,000 units of creams, more than half of which sales were made to retailers. Plaintiffs learned from defendants’ supplemental responses to plaintiffs’ second and third sets of special interrogatories that defendants’ revenue from the sale of both creams during the class period was approximately $2.5 million. [[End nonpublished portion.]] 3. The settlement The parties underwent mediation and conducted settlement discussions that continued after mediation. The parties reached a settlement of the action on behalf of the class (the settlement agreement). On November 20, 2013, they moved the trial court for preliminary certification of the class and approval of the stipulation of settlement.

4 [[Begin nonpublished portion.]] a. the settlement’s quid pro quo The settlement agreement identified one class, defined as “all persons in the United States who purchased one or more of Defendants’ Healing Cream or Control Cream from February 15, 2009 up to and including the Notice Date.” Defendants agreed to an injunction under which they would no longer market, advertise or sell either cream unless the labels and all descriptions and advertisements of the products disclosed all of the ingredients contained therein.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hansberry v. Lee
311 U.S. 32 (Supreme Court, 1940)
United States v. Seckinger
397 U.S. 203 (Supreme Court, 1970)
Brinker Restaurant Corp. v. Superior Court
273 P.3d 513 (California Supreme Court, 2012)
City of San Jose v. Superior Court
525 P.2d 701 (California Supreme Court, 1974)
United Bank & Trust Co. v. Hunt
34 P.2d 1001 (California Supreme Court, 1934)
Simons v. Horowitz
151 Cal. App. 3d 834 (California Court of Appeal, 1984)
Rebney v. Wells Fargo Bank
220 Cal. App. 3d 1117 (California Court of Appeal, 1990)
Ellena v. State of California
69 Cal. App. 3d 245 (California Court of Appeal, 1977)
Gainey v. Occidental Land Research
186 Cal. App. 3d 1051 (California Court of Appeal, 1986)
Consumer Privacy Cases
175 Cal. App. 4th 545 (California Court of Appeal, 2009)
California Insurance Guarantee Ass'n v. Workers' Compensation Appeals Board
12 Cal. Rptr. 3d 12 (California Court of Appeal, 2004)
Cellphone Termination Fee Cases
180 Cal. App. 4th 1110 (California Court of Appeal, 2009)
Steroid Hormone Product Cases
181 Cal. App. 4th 145 (California Court of Appeal, 2010)
Colgan v. Leatherman Tool Group, Inc.
38 Cal. Rptr. 3d 36 (California Court of Appeal, 2006)
Louie v. BFS Retail & Commercial Operations, LLC
178 Cal. App. 4th 1544 (California Court of Appeal, 2009)
Wershba v. Apple Computer, Inc.
110 Cal. Rptr. 2d 145 (California Court of Appeal, 2001)
Hernandez v. VITAMIN SHOPPE INDUSTRIES INC.
174 Cal. App. 4th 1441 (California Court of Appeal, 2009)
JP Morgan & Co., Inc. v. Superior Court
6 Cal. Rptr. 3d 214 (California Court of Appeal, 2003)
Kullar v. Foot Locker Retail, Inc.
168 Cal. App. 4th 116 (California Court of Appeal, 2008)
Chavez v. Netflix, Inc.
75 Cal. Rptr. 3d 413 (California Court of Appeal, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
Choi v. Restaino, Counsel Stack Legal Research, https://law.counselstack.com/opinion/choi-v-restaino-calctapp-2016.